Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer
September 05 2019 - 8:30AM
via NetworkWire — Genprex Inc. (NASDAQ: GNPX) today announces its
placement in an editorial published by NetworkNewsWire ("NNW"), a
multifaceted financial news and publishing company for private and
public entities.
To view the full publication, titled “Gene Therapy Treatments
Offer Hope for Cancer Patients,” visit: http://nnw.fm/k9gI7
Despite huge public awareness and a decrease in smoking, lung
cancer remains one of the most common types of cancer and is a
major killer in many countries. An estimated 2.09 million people
were affected by lung cancer worldwide in 2018, and 1.76 million of
them died. While prevention has improved, survival rates remain low
once the disease takes root.
Tackling cancer has become a huge issue for modern governments,
charities and health-care businesses. Companies such as
Genprex Inc. (NASDAQ:GNPX) have
put the whole focus of their operations on tackling the disease.
Whether aimed at curing the disease or extending the lives of
patients, these treatments are varied and often innovative. But the
very nature of cancer, in which a body’s own cells destroy it,
makes this difficult.
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing
potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s
initial product candidate, Oncoprex™ immunogene therapy for
non-small cell lung cancer (NSCLC). Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating
them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell-signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at www.genprex.com or follow Genprex on Twitter
at twitter.com/genprex, Facebook
at facebook.com/genprexinc and LinkedIn
at linkedin.com/company/genprex.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets, industries
and demographics in the most effective manner possible, (2) article
and editorial syndication to 5,000+ news outlets, (3) enhanced
press release services to ensure maximum impact, (4) social media
distribution via the Investor Brand Network (IBN) to nearly 2
million followers, (5) a full array of corporate communications
solutions, and (6) a total news coverage solution with NNW Prime.
As a multifaceted organization with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. By cutting through the overload of information in today’s
market, NNW brings its clients unparalleled visibility, recognition
and brand awareness. NNW is where news, content and information
converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024